In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

• Published in: International journal of molecular sciences 2023-11, Vol.24 (22), p.16411
• Main Authors: Kao, Yung-Tsung, Yen, Chih-Ching, Fan, Hueng-Chuen, Chen, Jen-Kun, Chen, Ming-Shan, Lan, Ying-Wei, Yang, Shang-Hsun, Chen, Chuan-Mu
• Format: Article
• Language: English
• Subjects: Amniotic fluid; Antibodies; Blood coagulation factor VIII; Chromosomes; Fetus; Fetuses; Flow cytometry; Gene therapy; Genetic aspects; Growth; Hemophilia; Hemorrhage; Liver; Medical equipment and supplies industry; Medical research; Medical test kit industry; Medicine, Experimental; Patients; Pregnant women; Stem cells; Vectors (Biology)
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242216411

Hemophilia is a genetic disorder linked to the sex chromosomes, resulting in impaired blood clotting due to insufficient intrinsic coagulation factors. There are approximately one million individuals worldwide with hemophilia, with hemophilia A being the most prevalent form. The current treatment for hemophilia A involves the administration of clotting factor VIII (FVIII) through regular and costly injections, which only provide temporary relief and pose inconveniences to patients. In utero transplantation (IUT) is an innovative method for addressing genetic disorders, taking advantage of the underdeveloped immune system of the fetus. This allows mesenchymal stromal cells to play a role in fetal development and potentially correct genetic abnormalities. The objective of this study was to assess the potential recovery of coagulation disorders in FVIII knockout hemophilia A mice through the administration of human amniotic fluid mesenchymal stromal cells (hAFMSCs) via IUT at the D14.5 fetal stage. The findings revealed that the transplanted human cells exhibited fusion with the recipient liver, with a ratio of approximately one human cell per 10,000 mouse cells and produced human FVIII protein in the livers of IUT-treated mice. Hemophilia A pups born to IUT recipients demonstrated substantial improvement in their coagulation issues from birth throughout the growth period of up to 12 weeks of age. Moreover, FVIII activity reached its peak at 6 weeks of age, while the levels of FVIII inhibitors remained relatively low during the 12-week testing period in mice with hemophilia. In conclusion, the results indicated that prenatal intrahepatic therapy using hAFMSCs has the potential to improve clotting issues in FVIII knockout mice, suggesting it as a potential clinical treatment for individuals with hemophilia A.